Form 4: Alkermes EVP Craig Hopkinson Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Craig Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, exercised stock options and sold shares of ordinary stock under a pre-arranged 10b5-1 trading plan.
Summary
- Craig C. Hopkinson, EVP R&D, Chief Medical Officer of Alkermes plc, filed a Form 4 detailing changes in beneficial ownership.
- On February 12, 2025, Hopkinson exercised options to acquire 87,566 shares at $20.03 and 111,630 shares at $19.34.
- Also on February 12, 2025, Hopkinson sold 171,813 shares at a weighted average price of $32.6914 and 33,108 shares at a weighted average price of $33.269.
- On February 13, 2025, Hopkinson exercised options to acquire 108,833 shares at $31.93 and 35,586 shares at $24.59.
- Also on February 13, 2025, Hopkinson sold 35,586 shares at a weighted average price of $34.0217 and 108,833 shares at a weighted average price of $36.0185.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2023.
- Following these transactions, Hopkinson directly owns 57,875 ordinary shares.
- Hopkinson also holds options to purchase 50,104 and 71,172 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock transactions by a company executive. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. The use of 10b5-1 plans allows insiders to sell shares over a period of time, avoiding concerns about insider trading.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
- The vesting schedules and exercise prices of these options are typically benchmarked against industry standards to attract and retain talent.
- The use of 10b5-1 trading plans is a standard practice among executives to manage their personal finances while complying with securities laws.
- Comparable companies in the biotechnology industry, such as Biogen and Vertex Pharmaceuticals, also have executives who utilize similar stock option and trading plan strategies.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
- However, the impact is likely to be minimal as the transactions were executed under a pre-arranged trading plan and represent a small percentage of the company's outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 12/14/2023 | Date of adoption of Rule 10b5-1 trading plan |
| 02/22/2022 | Commencement date for vesting of options to purchase 111,630 shares. |
| 02/18/2023 | Commencement date for vesting of options to purchase 35,586 shares. |
| 02/12/2025 | Date of stock option exercises and share sales |
| 02/13/2025 | Date of stock option exercises and share sales |
| 02/14/2025 | Date of Form 4 filing |
| 02/20/2030 | Expiration date of employee stock options to buy 87,566 shares |
| 02/21/2029 | Expiration date of employee stock options to buy 108,833 shares |
| 02/22/2031 | Expiration date of employee stock options to buy 111,630 shares |
| 02/18/2032 | Expiration date of employee stock options to buy 35,586 shares |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.